Related Experiment Videos
Rotavirus vaccines: is the second time the charm?
1Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. dick.ward@cchmc.org
Current Opinion in Investigational Drugs (London, England : 2000)
|August 27, 2005
Summary
Rotavirus vaccines utilize live, attenuated oral strains to mimic natural infections. Development has progressed from animal strains to human-rotavirus reassortments and cell-culture-attenuated vaccines, improving efficacy and safety for rotavirus disease prevention.
Area of Science:
- Vaccinology
- Virology
- Pediatric Infectious Diseases
Background:
- Live, oral rotavirus vaccines aim to mimic natural infection for effective immunization.
- Early vaccine candidates involved animal rotavirus strains attenuated for human use.
- Subsequent development focused on reassortant and human-derived strains to enhance protection and safety.
Observation:
- Initial rotavirus vaccine candidates, based on animal strains, showed inconsistent efficacy.
- Multivalent vaccines were created by reassorting animal and human rotavirus strains.
- RotaShield, a reassortant vaccine, was withdrawn from the US market due to intussusception risks.
Findings:
- Newer rotavirus vaccines, such as Rotateq and Rotarix, are expected or available.
- Rotarix is a human rotavirus strain attenuated through cell culture passage.
- These advancements aim to provide safer and more effective rotavirus prevention.
Implications:
- The evolution of rotavirus vaccines demonstrates progress in addressing global diarrheal disease burden.
- Ongoing vaccine development seeks to balance efficacy, safety, and broad applicability.
- Successful rotavirus vaccination strategies are crucial for reducing childhood mortality and morbidity worldwide.